Sugi Predict

Sugi Predict / Compounds / SCHEMBL3590890

SCHEMBL3590890

SCHEMBL3590890

O=C1CCOC(COCc2ccccc2)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.52
▸ PTPN1 P18031 2/20 0.43
▸ CDC25B P30305 1/20 0.43
▸ TSHR P16473 1/20 0.40
▸ AKT1 P31749 1/20 0.40
▸ DRD1 P21728 1/20 0.40
▸ TAAR1 Q96RJ0 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HRH4 Q9H3N8 4/20 0.39
▸ HRH3 Q9Y5N1 4/20 0.39
▸ BCHE P06276 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ BUB1 O43683 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25307505 0.85 LMNA (0.55) LMNAPTPN1CDC25BTSHRAKT1
SCHEMBL25307508 0.85 LMNA (0.55) LMNAPTPN1CDC25BTSHRAKT1
SCHEMBL14635790 0.80 GRM2 (0.43) TSHRPOLBHTT
SCHEMBL10420228 0.79 LMNA (0.54) LMNATSHRDRD1TAAR1HRH4
SCHEMBL19559233 0.79 LMNA (0.54) LMNATSHRDRD1TAAR1HRH4
SCHEMBL15969170 0.79 LMNA (0.63) LMNAPTPN1CDC25BTSHRAKT1
SCHEMBL15969169 0.79 LMNA (0.63) LMNAPTPN1CDC25BTSHRAKT1
SCHEMBL6958085 0.79 TDP1 (0.57) TSHRCYP3A4HRH3
SCHEMBL15683024 0.77 DRD4 (0.49) CYP3A4CYP2C9
SCHEMBL420813 0.77 LMNA (0.52) LMNAPTPN1CDC25BTSHRAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP disclosed
WO-2025235389-A1 P53 MODULATORS NESTED THERAPEUTICS, INC. (US) 2025-11-13 — — WO disclosed
WO-2024215802-A1 BENZOFURANYL AND BENZOTHIENYL COMPOUNDS AS P53 MODULATORS NESTED THERAPEUTICS, INC. (US) 2024-10-17 — — WO disclosed
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2024-03-28 — — US disclosed
EP-3592741-B1 NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS PFIZER (US) 2023-02-15 — — EP disclosed
EP-3592741-B1 NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS PFIZER (US) 2023-02-15 — — EP disclosed
CN-111051304-B Imidazo [4,5-c ] quinoline derivatives as LRRK2 inhibitors 辉瑞大药厂 2022-12-27 — — CN disclosed
WO-2022132696-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-06-23 — — WO disclosed
US-11312713-B2 Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors PFIZER INC. (US) 2022-04-26 — — US disclosed
US-11312713-B2 Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors PFIZER INC. (US) 2022-04-26 — — US disclosed
WO-2016069376-A1 NOVEL METHYL-PIPERIDINE COMPOUNDS USEFUL FOR INHIBITING MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 ELI LILLY AND COMPANY (US) 2016-05-06 — — WO disclosed
US-20100004222-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same RENOVIS, INC. (US) 2010-01-07 — — US disclosed
US-20100004222-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same RENOVIS, INC. (US) 2010-01-07 — — US disclosed
EP-1954132-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2008-08-13 — — EP disclosed
WO-2007100758-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-09-07 — — WO disclosed
US-6638955-B2 Antibiotic oxazolidinone derivatives SYNGENTA LIMITED (GB) 2003-10-28 — — US disclosed
US-20020133022-A1 Antibiotic oxazolidinone derivatives SYNGENTA LIMITED (GB) 2002-09-19 — — US disclosed
US-6365751-B1 ACTIVE AGAINST GRAM-POSITIVE BACTERIA, IN PARTICULAR, AGAINST STRAINS RESISTANT TO VANCOMYCIN, AMINOGLYCOSIDES AND PENCILLINS AND DERIVATIVES; NONTOXIC ZENECA LTD. (GB) 2002-04-02 — — US disclosed
US-6271383-B1 USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. ZENECA LIMITED (GB) 2001-08-07 — — US disclosed
US-5981528-A Antibiotic oxazolidinone derivatives ZENECA LIMITED 1999-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004222-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same TRPV1, TRPA1, TRPV2 LMNA 2439/4885PTPN1 2094/4885CDC25B 2968/4885
US-11312713-B2 Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors LRRK2, PARK7, BRCA1 LMNA 2226/4885PTPN1 1558/4885CDC25B 596/4885
US-20020133022-A1 Antibiotic oxazolidinone derivatives OXA1L, POLN, MRPL21 LMNA 1055/4885PTPN1 2906/4885CDC25B 2784/4885
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS HCRTR1, HCRTR2, UTS2R LMNA 3767/4885PTPN1 3665/4885CDC25B 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.